Table 2 Characteristics of patients newly initiated on paliperidone palmitate and risperidone microsphere

Total

25,361 (100%)

9,720 (100%)

14,461 (100%)

1,180 (100%)

Gender

 Women

10,014 (39%)

3,472 (36%)

6,022 (42%)

520 (44%)

 Men

15,347 (61%)

6,248 (64%)

8,439 (58%)

660 (56%)

Age

 18–30 years

4,687 (18%)

2,236 (23%)

2,451 (17%)

-

 31–50 years

11,348 (45%)

4,906 (50%)

6,442 (45%)

-

 > 50 years

8,146 (32%)

2,578 (27%)

5,568 (39%)

-

Type of treatment

 Paliperidone palmitate

18,028 (71%)

7,463 (77%)

9,756 (67%)

809 (69%)

 Risperidone microspheres

7,333 (29%)

2,257 (23%)

4,705 (33%)

371 (31%)

Previous treatment

 Other LAT

4,658 (18%)

1,807 (19%)

2,736 (19%)

115 (10%)

 Oral AP

9,456 (37%)

2,902 (30%)

6,146 (43%)

408 (35%)

 No AP

11,247 (44%)

5,011 (52%)

5,579 (39%)

657 (56%)

Average dosage per 30 days^a

 < 75 mg

5,000 (20%)

1,787 (18%)

2,889 (20%)

324 (27%)

 75–125 mg

13,208 (52%)

4,708 (48%)

7,968 (55%)

532 (45%)

 > 125 mg

7,153 (28%)

3,225 (33%)

3,604 (25%)

324 (27%)

Combination therapy

 Monotherapy

12,480 (49%)

5,574 (57%)

6,252 (43%)

654 (55%)

 Combination therapy

12,881 (51%)

4,146 (43%)

8,209 (57%)

526 (45%)

Specialty of the prescribers

 GP only

1,867 (7%)

622 (6%)

831 (6%)

414 (35%)

 Psychiatrist + GP

2,736 (11%)

1,074 (11%)

1,310 (9%)

352 (30%)

 Psychiatrist only

19,492 (77%)

7,485 (77%)

11,634 (80%)

373 (32%)

 Other

1,266 (5%)

539 (6%)

686 (5%)

41 (3%)

Other treatments^b

 None

6,676 (26%)

1,220 (13%)

5,267 (36%)

189 (16%)

 1 molecule

3,612 (14%)

1,128 (12%)

2,292 (16%)

192 (16%)

 2 molecules

3,167 (12%)

1,193 (12%)

1,778 (12%)

196 (17%)

 > 2 molecules

11,906 (47%)

6,179 (64%)

5,124 (35%)

603 (51%)